View Press Releases

Insight Pharma Reports Announces Digital PCR Technology Report: An Insight to Vendors, Costs & the End User Community

November 30, 2013

NEEDHAM, MASS. - Cambridge Healthtech Institute's Insight Pharma Reports announces Digital PCR Technology Report: An Insight to Vendors, Costs & the End User Community.

The newly released Insight Pharma Report is about the digital PCR technologies that have surfaced in the market. Digital PCR is a new application in research and development allowing for higher sensitivity and specificity than real-time PCR. This allows researchers to closely examine rare genetic mutations (including single nucleotide polymorphisms), copy number variations, viruses, prenatal defects, and much more. National measurement institutions have also been looking into digital PCR as a reference standard as well as using its precision and accuracy to create reference standards for diagnostic labs.  

This report focuses on the main vendors supplying digital PCR systems, validation of the instruments, and digital PCR's impact in research. By detecting rare sequences that were previously undetected with real-time PCR, digital PCR has enabled scientists to accelerate their research. However, there are many areas of the new technology that have been overlooked and neglected, and this report covers those aspects as well.  

Also included in this report are: 

  • Feedback from end-user communities including
    • Ease of use
    • Sample preparation
    • Integration with real-time PCR assays
    • Areas of improvement
    • Customer satisfaction
     
  • Interviews with the main vendors in the market space including
    • RainDance Technologies
    • Bio-Rad Laboratories
    • Life Technologies
    • Fluidigm Corporation
     
  • Interviews with national measurement institutions including
    • National Institute of Standards and Technology (NIST)
    • LGC Group
    • National Measurement Institute (NMI) Australia
     
  • Six tables including a comparison table with specifications of the digital PCR instruments including
    • Type of platform
    • Number of reactions per sample
    • Number of samples the instruments can run or analyze
    • Type of detection (end-point or real-time)
    • Reaction volume
    • Total volume
    • Cost per products
    • Cost per run
    • Cost per sample
    • Cost per 10,000 reactions
       
     
  • Results depicted over 12 charts and graphs
  • Detailed descriptions of the platforms available
  • In-depth survey results from over 220 participants.  Results are from Academic/University, Biotechnology, Pharmaceutical, Government Clinical and Other technology providers - and cover their familiarity of digital PCR and vendors, and expected future use. 

 

For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com or contact Kerri Simpson at ksimpson@healthtech.com or 781-972-1347.

 

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.  http://www.InsightPharmaReports.com
 

Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/affiliatedreports/